Compare Citius Pharmaceuticals Inc (CTXR) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $30.33. The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | QDTE | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $36.60 |
52-Week Low | $0.53 | $26.85 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
QDTE (Roundhill Innovation-100 0DTE Covered Call Strategy ETF) trades at $29.98, down 1.69% with a bearish technical signal. The ETF employs a weekly covered call strategy on Nasdaq-100 components, generating high distribution yields through 0DTE options. Recent dividend payments show consistent weekly distributions, though the yield has compressed as volatility declined. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
The ETF faces headwinds from declining volatility reducing option premiums, potentially impacting future distribution rates. While the weekly income stream appeals to income investors, the strategy's sustainability depends on market conditions. Current technical weakness suggests near-term pressure, though the high-yield strategy remains attractive for income-focused portfolios in stable markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
